HIM
YMAB

Hillsdale Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Hillsdale Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,699
Closed -$902K – 647
2021
Q2 		$902K Buy
+26,699
New +$857K 0.07% 281

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Hillsdale Investment Management's YMAB Position: Q3 2021 in Review

Hillsdale Investment Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2021, closing a stake of 26,699 shares — an estimated $902K sold.

Hillsdale Investment Management first reported a position in YMAB in Q2 2021 and held it in 1 quarter. The position peaked at $902K in Q2 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q3 2021.

  • Hillsdale Investment Management reported no remaining Y-mAbs Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 26,699 Y-mAbs Therapeutics shares in Q3 2021, an estimated $902K.
  • Hillsdale Investment Management first reported a position in Y-mAbs Therapeutics in Q2 2021 and held it in 1 quarter.
  • Hillsdale Investment Management's Y-mAbs Therapeutics position peaked at $902K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2021.

Based on Hillsdale Investment Management's 13F filing for Q3 2021, filed 21 Oct 2021.